Immunoneutralization of procalcitonin or its component peptides: a promising treatment of sepsis

被引：4

作者：

Becker, Kenneth L. ^{[1
,2
]}

机构：

[1] George Washington Univ, Washington, DC 20037 USA

[2] Vet Affairs Med Ctr, Washington, DC 20037 USA

来源：

CLINICAL SCIENCE | 2010年 / 119卷 / 11-12期

关键词：

adrenocorticotropic hormone (ACTH); aminoprocalcitonin peptide (N-PCT); cytokine; mortality; procalcitonin; septic shock;

D O I：

10.1042/CS20100367

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Sepsis and the severe systemic response syndrome are very common illnesses that are responsible for a great amount of morbidity and death. These closely related conditions are characterized by a remarkable increase in the prohormone ProCT (procalcitonin). ProCT is both a marker of sepsis and a harmful mediator of the disease. In the present issue of Clinical Science, in a study in rats with endotoxin shock, Tavares and Minano used an antibody to a segment of N-ProCT (aminoprocalcitonin) that is part of the ProCT molecule, and confirmed that immunoneutralization of ProCT saves the animals from this severe illness. Furthermore, they extensively studied the epiphenomena associated with this immunoneutralization.

引用

页码：515 / 517

页数：3

共 11 条

[1]

[Anonymous], INCIDENCE MORTALITY

[2] HIGH SERUM PROCALCITONIN CONCENTRATIONS IN PATIENTS WITH SEPSIS AND INFECTION [J].

ASSICOT, M ;

GENDREL, D ;

CARSIN, H ;

RAYMOND, J ;

GUILBAUD, J ;

BOHUON, C .

LANCET, 1993, 341 (8844) :515-518

[3] Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target [J].

Becker, Kenneth L. ;

Snider, Richard ;

Nylen, Eric S. .

BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (02) :253-264

[4] Animal models of sepsis and sepsis-induced kidney injury [J].

Doi, Kent ;

Leelahavanichkul, Asada ;

Yuen, Peter S. T. ;

Star, Robert A. .

JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (10) :2868-2878

[5] 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference [J].

Levy, MM ;

Fink, MP ;

Marshall, JC ;

Abraham, E ;

Angus, D ;

Cook, D ;

Cohen, J ;

Opal, SM ;

Vincent, JL ;

Ramsay, G .

CRITICAL CARE MEDICINE, 2003, 31 (04) :1250-1256

[6]

Martinez J M, 2001, Surg Infect (Larchmt), V2, P193, DOI 10.1089/109629601317202678

[7] Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis [J].

Nylen, ES ;

Whang, KT ;

Snider, RH ;

Steinwald, PM ;

White, JC ;

Becker, KL .

CRITICAL CARE MEDICINE, 1998, 26 (06) :1001-1006

[8] The Surviving Sepsis Campaign: raising awareness to reduce mortality [J].

Slade, E ;

Tamber, PS ;

Vincent, JL .

CRITICAL CARE, 2003, 7 (01) :1-2

[9] Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor® System [J].

Steinbach, G ;

Rau, B ;

Debard, AL ;

Javourez, JF ;

Bienvenu, J ;

Ponzio, A ;

Bonfà, A ;

Hubl, W ;

Demant, T ;

Külpmann, WR ;

Buchholz, J ;

Schumann, G .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2004, 42 (04) :440-449

[10] Immunoneutralization of the aminoprocalcitonin peptide of procalcitonin protects rats from lethal endotoxaemia: neuroendocrine and systemic studies [J].

Tavares, Eva ;

Minano, Francisco J. .

CLINICAL SCIENCE, 2010, 119 (11-12) :519-534

← 1 2 →